Onkológia 4/2013

Treatment of indolent B-cell lymphomas by the personalized cancer vaccine BiovaxID

BiovaxID is personalized antilymphoma cancer vaccine intended to the treatment of indolent B-cells non-Hodgkin’s lymphoma. Vaccine represents the first of a new class of cancer vaccines designed for patients who have successfully achieved complete remission 6-12 months after treatment completion. Biovax stimulates the patient’s own T-cells to recognize and destroy the cancerous B-cells that extend disease-free survival and prevent lymphoma from returning. In 2008 Biovax completed Phase III clinical trials, which have shown that vaccine is safe, well-tolerated and significantly prolonged disease-free survival from 33.6 to 44.2 months in patients with follicular lymphoma. At present, the approval process of Biovax vaccine for the treatment of follicular lymphoma is ongoing by the U.S. FDA, Health Canada and European EMA.

Keywords: personalized antilymphoma cancer vaccine, indolent B-cell lymphomas.